LL-37 is a 37-amino-acid human cathelicidin-derived peptide used in research involving innate immune signaling, antimicrobial activity, inflammation, cellular migration, and tissue-response pathways. It corresponds to the active C-terminal region of the human cathelicidin precursor hCAP-18 and has a strongly cationic, amphipathic structure that contributes to its interaction with microbial membranes and host-cell signaling systems. PubChem lists LL-37 with the sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES, molecular formula C₂₀₅H₃₄₀N₆₀O₅₃, and molecular weight of approximately 4493 g/mol.
Research on LL-37 has examined its ability to disrupt microbial membranes, neutralize lipopolysaccharide activity, regulate inflammatory responses, influence leukocyte signaling, and stimulate endothelial-cell activity. Experimental studies have also evaluated LL-37 in relation to angiogenesis, endothelial proliferation, keratinocyte migration, and wound-associated tissue responses. One landmark study reported LL-37-mediated endothelial activation and angiogenesis through formyl-peptide-receptor-like signaling, while later clinical research has examined topical LL-37 in wound-healing models. These findings describe experimental and clinical research contexts rather than claims for research-product use.
ATTENTION: All Unique ChemX products featured here are intended exclusively for research and development purposes. They are not designed for any form of human or animal consumption. These products have not undergone evaluation by the U.S. Food and Drug Administration.




